Information Provided By: 
Fly News Breaks for July 20, 2017
CEMP, PRTK
Jul 20, 2017 | 10:04 EDT
Cantor Fitzgerald analyst Louise Chen says the two day selloff in shares of Paratek Pharmaceuticals (PRTK) after "positive and competitive" data from the company's OASIS-2 trials is overdone. The issues experienced by Cempra's (CEMP) community antibiotic product are entirely product-specific and not a read-through to Paratek, Chen told investors last night in a research note. She believes Paratek will be able to market Omadacycline effectively if it is approved and keeps an Overweight rating on the shares with a $50 price target.
News For PRTK;CEMP From the Last 2 Days
There are no results for your query PRTK;CEMP
